You are here: Home: HOU 1 | 2008 Audio: HOU 1 | 2008
 
 
  Go to interview with Susan M O’Brien, MD
Go to interview with Robert Z Orlowski, MD, PhD
Go to interview with David P Steensma, MD
Go to interview with David G Maloney, MD, PhD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
O'Brien, MD Susan M O’Brien, MD
Professor of Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Monitoring patients with chronic myelogenous leukemia (CML) who are receiving tyrosine kinase therapy
Track 2 Monitoring patients who have achieved a complete cytogenetic remission
Track 3 Rationale for dose escalation of imatinib in CML
Track 4 Side effects associated with higher-dose imatinib
Track 5 Efficacy and toxicity of dasatinib at 100 milligrams per day
Track 6 Utility of FISH in monitoring patients during treatment

Track 7 BCR-ABL kinase domain mutation analysis to guide secondary tyrosine kinase inhibitor treatment
Track 8 Selection of nilotinib or dasatinib after imatinib failure
Track 9 Null association between imatinib and cardiac abnormalities
Track 10 IRIS trial six-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed, chronic-phase CML treated with imatinib
Track 11 Historical rationale for observation of patients with newly diagnosed chronic lymphocytic leukemia (CLL)
Track 12 Prognostic factors for the identification of patients with high-risk CLL
Track 13 Clinical relevance of prognostic factors to selection of therapy
Track 14 Use of consolidation alemtuzumab to eliminate residual disease after response to fludarabine-based therapy
Track 15 Side effects and toxicity of alemtuzumab
Track 16 Alemtuzumab and cytomegalovirus reactivation
Track 17 International Phase III trial of bendamustine versus chlorambucil in treatment-naïve B-cell CLL
Track 18 Utility of consolidation therapy for minimal residual disease in CLL
Track 19 Future treatment of CML and CLL
     
Orlowski, MD, PhD Robert Z Orlowski, MD, PhD
Director, Department of
Lymphoma and Myeloma
Associate Professor, Department of
Experimental Therapeutics
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Emergence of Phase III data with novel agents as first-line therapy for multiple myeloma (MM)
Track 2 SWOG-S0232: Superiority of lenalidomide with high-dose dexamethasone compared to dexamethasone alone for newly diagnosed MM
Track 3 ECOG-E4A03: Lenalidomide with high-dose or low-dose dexamethasone in newly diagnosed MM
Track 4 Induction bortezomib/dexamethasone versus vincristine/doxorubicin/dexamethasone (VAD) prior to autologous stem cell transplantation (ASCT) for newly diagnosed MM
Track 5 Italian study of induction thalidomide/dexamethasone with or without bortezomib in preparation for ASCT in newly diagnosed MM
Track 6 Mechanism(s) of action of proteosome inhibitors
Track 7 Melphalan/prednisone with or without thalidomide for patients with newly diagnosed MM who are ineligible for transplantation

Track 8 VISTA trial results: Melphalan/prednisone with or without bortezomib for newly diagnosed MM
Track 9 Use of “IMiD”-based (thalidomide or lenalidomide) regimens versus bortezomib-based regimens for newly diagnosed MM
Track 10 Efficacy and tolerability of lenalidomide/dexamethasone and thalidomide/dexamethasone
Track 11 International Myeloma Working Group consensus on prophylaxis for IMiD-associated thrombosis
Track 12 Safety and efficacy of bortezomib/lenalidomide with dexamethasone for newly diagnosed MM
Track 13 Potential impact of novel agents on the future role of transplantation in MM
Track 14 Role of maintenance therapy after transplantation
Track 15 Improved time to progression with pegylated liposomal doxorubicin with bortezomib compared to bortezomib alone in relapsed or refractory MM
Track 16 Selection of patients for treatment with liposomal doxorubicin and bortezomib
Track 17 Key ongoing trials in MM
     
Steensma, MD David P Steensma, MD
Associate Professor of
Medicine and Oncology
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, Minnesota		  
  Click here to download the entire interview  
Track 1 AZA-001: Azacitidine prolongs overall survival in higher-risk myelodysplastic syndrome (MDS) compared to conventional care regimens
Track 2 Clinical trials evaluating azacitidine in combination with histone deacetylase inhibitors
Track 3 Counseling patients about the similarities and differences between MDS and cancer
Track 4 Common questions about the treatment of MDS
Track 5 Treatment algorithm for patients with newly diagnosed MDS
Track 6 Newly recognized cytogenetic abnormalities not included in the International Prognostic Scoring System

Track 7 Incidence of MDS in the US
Track 8 Case discussion: A man in his seventies with high-risk (INT-2) platelet transfusion-dependent MDS
Track 9 Case follow-up: Complete remission and freedom from transfusion after treatment on a demethylating agent
Track 10 Case discussion: A 75-year-old woman with isolated del(5q) syndrome
Track 11 Case follow-up: Two-year response to lenalidomide on a clinical trial
Track 12 Case discussion: A 60-year-old man with high-risk MDS

Track 13 Case follow-up: Azacitidine followed by umbilical cord transplantation
Track 14 Emerging treatment options in MDS

     
Maloney, MD, PhD David G Maloney, MD, PhD
Associate Member
Clinical Research Division
Fred Hutchinson Cancer
Research Center
Associate Professor of Medicine
Division of Oncology
University of Washington
Seattle, Washington		  
  Click here to download the entire interview  
Track 1 Advances associated with the use of rituximab for follicular lymphoma
Track 2 Radiolabeled antibody therapy in the treatment of follicular lymphoma
Track 3 Potential role of bendamustine in the treatment of follicular lymphoma
Track 4 Improved clinical outcomes with maintenance rituximab in follicular lymphoma
Track 5 Ongoing clinical trials evaluating maintenance rituximab in follicular lymphoma
Track 6 Clinical algorithm for the use of maintenance rituximab

Track 7 R-CHOP versus R-hyper-CVAD in the treatment of mantle-cell lymphoma
Track 8 Incorporation of bortezomib into the treatment of mantle-cell lymphoma
Track 9 Safety and efficacy of nonmyeloablative allogeneic stem cell transplantation in mantle-cell lymphoma
Track 10 R-CHOP-14 versus R-CHOP-21 for diffuse large B-cell lymphoma (DLBCL)

Track 11 Development of novel antibodies for the treatment of DLBCL
Track 12 Clinical utility of allogeneic hematopoietic cell transplantation in the lymphomas and CLL